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Background: Many species of non-human primates in Africa are naturally infected by simian immunodeficiency
viruses (SIV) and humans stand at the forefront of exposure to these viruses in Sub-Saharan Africa. Cross-species
transmission and adaptation of SIV to humans have given rise to human immunodeficiency viruses (HIV-1 and HIV-2)
on twelve accountable, independent occasions. However, the determinants contributing to a simian-to-human
lasting transmission are not fully understood. Following entry, viral cores are released into the cytoplasm and
become the principal target of host cellular factors. Here, we evaluated cellular factors likely to be involved in
potential new SIV cross-species transmissions. We investigated the interactions of capsids from naturally circulating SIV
isolates with both HIV-1 restricting (i.e. TRIM5 proteins) and facilitating (i.e. cyclophilin A and nucleopore-associated
Nup358/RanBP2 and Nup153) factors in single-round infectivity assays that reproduce early stages of the viral life-cycle.
Results: We show that human TRIM5α is unlikely to prevent cross-species transmission of any SIV we tested and
observed that the SIV CA-CypA interaction is a widespread but not a universal feature. Moreover, entry in the nucleus of
different SIV appeared to follow pathways that do not necessarily recruit Nup358/RanBP2 or Nup153, and this regardless
of their interaction with CypA. Nevertheless, we found that, like HIV-1, human-adapted HIV-2 infection was dependent on
Nup358/RanBP2 and Nup153 interactions for optimal infection. Furthermore, we found that, unlike HIV CA, SIV CA did not
require a direct interaction with the Cyp-like domain of Nup358/RanBP2 to carry out successful infection.
Conclusions: Circulating SIV present a variety of phenotypes with regard to CA-interacting restricting or facilitating
factors. Altogether, we unveiled unidentified pathways for SIV CA, which could also be exploited by HIV in different
cellular contexts, to drive entry into the nucleus. Our findings warrant a closer evaluation of other potential defenses
against circulating SIV.
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Retroviruses are known to overcome species barriers and
there is now significant evidence that the AIDS epidemics
resulted from several cross-species transmissions from
primates to humans. Simian immunodeficiency viruses
(SIV) form a large group of related viruses which are
naturally endemic to a wide variety of African nonhuman
primate species. To date, serological evidence of SIV in-
fection has been reported in at least 45 Old World monkey
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reproduction in any medium, provided the orhave been characterized from most of them [1]. SIV have
a long history of simian-to-simian transmissions [2-4]. Thus,
the progenitor of the human immunodeficiency virus type 1
(HIV-1), SIVcpz, isolated from chimpanzees, is a recom-
binant virus derived from two viruses that infect Old World
monkey species [5]. Moreover, at least 11 independent
cross-species transmissions of SIV from chimpanzees (Pan
troglodytes troglodytes) and sooty mangabeys (Cercocebus
atys) to humans have given rise to HIV-1 and HIV-2, re-
spectively [6-8]. More recently a twelfth independent trans-
mission has been described with the isolation of a new
group of HIV-1, P, in a Cameroonian woman. HIV-1 P is
closely related to an SIV found in gorillas (Gorilla gorilla)
in the wild [9]. Therefore, a large pool of SIV that are
widely distributed in Sub-Saharan Africa represents a po-
tential risk for the exposed human population [10,11].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ful SIV cross-species infection remains rather rare since
the majority of the SIV characterized so far, have no
known human counterparts. Nevertheless, little is known
about the factors that can potentially contribute to, or
restrict, simian-to-human transmissions. The SIV tropism
for new species is determined by their ability to exploit
particular cellular host proteins for their replication while
counteracting inhibiting factors. In primates, several clas-
ses of retroviral cellular restrictions have been identified
at different steps of the retroviral cycle, including cyti-
dine deaminases (e.g. APOBEC3G) [12], CD317/tetherin
[13,14], SAMHD1 [15,16] and TRIM5α proteins [17].
Interestingly, it has been shown that all these proteins
display signatures of positive selection throughout many
primate lineages [18-21] indicative of an ongoing host/
virus history.
Following binding of virions to cellular receptors and
entry into the cell, the viral capsid (CA) is released into
the cytoplasm. Thus, CA constitutes an early target for
host cellular factors that are either required for lentivirus
replication or have anti-retroviral properties. One of the
earliest identified post-entry restriction factors, TRIM5α,
acts before reverse transcription [17]. TRIM5α is a mem-
ber of the large family of tripartite motif proteins (TRIM)
that contain RING, B-box, and coiled-coil domains with
an additional C-terminal PRYSPRY domain, which is
required for its antiretroviral activity [22]. TRIM5α re-
stricts retroviruses in a virus-specific and species-specific
way. For example, rhesus monkey (rh) or African green
monkey (agm) TRIM5α potently restricts HIV-1, whereas
human TRIM5α has no significant detectable effect on
HIV-1; in contrast human TRIM5α potently restricts
N-tropic murine leukemia virus (N-MLV) [23-25], a
widespread and phylogenetically very distant mouse
gammaretrovirus. Interestingly, it has recently been de-
scribed that some HIV-2 strains are sensitive to human
TRIM5α [26]. TRIM5α is a cellular E3 ubiquitin ligase,
that recognizes incoming multimerized viral cores and
accelerates uncoating of retroviral capsids [27,28]. More
recently, it has been described that TRIM5α can act as a
pattern recognition receptor (PRR), promoting innate
immune signaling in response to retroviral infection
[29]. The CA protein of HIV-1 also interacts with high
affinity to the host protein cyclophilin A (CypA) [30].
CypA, encoded by the peptidyl prolyl isomerase A gene
(PPIA), has been shown to be important for efficient
HIV-1 replication either by promoting uncoating [31] or
by protecting the CA from an unidentified restriction
factor [32-34]. Intriguingly, in the New World owl monkeys
(Aotus sp.), TRIM5α is replaced by TRIMCyp in which a
CypA pseudogene is fused to the Linker 2 region, substi-
tuting for the SPRY domain [35,36]. More recently, similar
but independent TRIM-Cyp gene fusions have been alsodiscovered in different species of Old World monkeys, such
as rhesus macaques (Macaca mulatta) and cynomolgus
macaques (Macaca fascicularis), highlighting the repro-
ducible evolutionary advantages provided by this gene
fusion [37]. Owl-TRIMCypA and mafa-TRIMCypA pro-
teins were described to efficiently block HIV-1 infection
while mamu-TRIMCypA was shown to block infection
by HIV-2 [38]. Therefore, CypA binding to viral CA is
an evolutionary widespread feature and likely to be re-
quired by multiple HIV/SIV lineages.
Recently, large-scale RNA interference screens have re-
vealed numerous host protein factors influencing HIV-1
infection, bringing to light potential new pathways in the
viral life cycle [39-43]. In contrast to other retroviruses,
lentiviruses have developed specific mechanisms for the
productive infection of non-dividing cells [44] and it has
been shown that the capsid plays an important role for
this property of HIV-1 [45-48]. Alhough the mechanisms
used by the HIV-1 pre-integration complexes (PIC) to
enter into the nucleus are not fully understood, a small
overlap between independent screens highlight several
critical co-factors known to play independently a role
in the nuclear import of the HIV-1 PIC [49-51]. Indeed,
depletion of the nuclear pore complex component Nup153
or the nuclear transport factor Nup358/RanBP2 hindered
nuclear import of HIV-1 and SIVmac [52-55]. Additionaly,
it has been shown that depletion of the karyopherin
transportin 3 (TNPO3) strongly decreases the infectivity
of HIV-1 through a specific block of integration following
nuclear import [53,56-58]. Nup153 and Nup358/RanBP2
are present in nuclear pore complexes (NPC) and seem to
actively regulate nuclear entry of viral PIC [45,54,57,59,60].
Nup358/RanBP2, is located at the cytoplasmic side of the
pore and has a C-terminal cyclophilin-like domain [61].
Given that HIV-1 can interact directly with this domain,
it has been hypothesized that this motif could be re-
sponsible for the recognition of incoming capsids and
thus mediating nuclear import [62,63].
Most of the knowledge regarding successive steps in
lentiviral replication comes from studies using prototypic
HIV-1 or SIVmac. However, much less is known on the
intrinsic capabilities of SIV isolates that circulate in the
wild to achieve productive infections in human cells,
notably because corresponding infectious molecular clones
are not available. Capsids play an essential role in the early
stages of viral replication and, as highlighted in a multiple
alignment of primate lentiviral CA protein sequences, they
harbor both highly divergent and conserved residues,
including within the CypA-binding loop.
Here, we have defined the susceptibilities of SIV CA to
human or simian proteins known to interact with HIV-1
CA, i.e. the cytoplasmic TRIM5 proteins, CypA and the
nucleopore-associated Nup358/RanBP2 and Nup153 fac-
tors. We chose to study SIV isolates amplified from small
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meat in West Central Africa (SIVgsn lineage, SIVcol
and SIVmnd1).
Results
In order to study the susceptibility of different SIV cores
to human or simian TRIM5α, we derived gag-pol con-
structs with the SIVmac background in which we replaced
CA with that of either HIV-1 or different circulating SIV.
Because Gag protein sequences of lentiviral primate line-
ages are highly diverse (Figure 1), we first validated our
strategy by inserting HIV-1 matrix-capsid (MACA) or
capsid (CA) sequences in place of the corresponding
region of an SIVmac251 gag-pol expression vector. Upon
transfection into HEK-293T cells, VSV-G pseudotyped
eGFP-expressing chimeric HIV MACA or CA virions
were produced and we verified the correct p55Gag pro-
teolytic cleavage by detecting the presence of CAp24 in
virus pellets (Figure 2A). The infectivity of the corre-
sponding virions was then tested on non-restrictive CHO
cells and CHO cells stably transduced with retroviral
vectors carrying either the human or one of the simian
HA-tagged-TRIM5 genes. Similar amounts of TRIM5α
(Figure 2B) and TRIM-Cyp (Figure 2C) proteins wereFigure 1 Capsid sequences of circulating SIV are highly variable. Align
SIVmac251 and HIV-1 (pNL4-3) with those of SIV circulating in the wild, SIV
(Cercopithecus mona); SIVgsn-99CM71 accession No. AF468658, from greate
accession No. AY340700, from mustached monkey (Cercopithecus cephus), S
SIVcolCGU1 accession No. AF301156) from mantled guereza (Colobus guere
with dashes. Arrows indicate the positions of the primers used to generate
is indicated by a star on top of the proline residue as well as the G89 and
corresponding residues.expressed in the transduced cells. As shown in Figure 2E,
the parental SIVmac vector infected equally well both
CHO derivatives whereas infection by SIVmac constructs,
in which HIV-1 MACA or CA were swapped, was de-
creased in agm-TRIM5α expressing cells, thus reprodu-
cing the restriction pattern observed with wild type
HIV-1 CA. We subsequently substituted the MACA or
CA-coding sequences of SIVmac by those of the different
SIV of the SIVgsn lineage (SIVgsn from greater spot-nosed
monkeys, SIVmon from mona monkeys and SIVmus-1
from mustached monkeys), SIVcol from Colobus guereza
monkeys, SIVmnd1 from mandrills and a HIV-1 CypA
binding mutant (CA G89V). All VSV-G pseudotyped
eGFP-expressing chimeric MACA or CA SIV vectors
were infectious on CHO cells and were subsequently
used at M.O.I ranging from 0.05 to 0.35. For the ensuing
studies, we chose the MACA or CA chimera that gave
the highest titer for each of the SIV isolates studied
(Figure 2D).
CA from circulating SIV isolates are not susceptible to
human or chimpanzee TRIM5α
Since amino acid sequence variations in CA determine
viral susceptibility to TRIM5α restriction, we tested thement of matrix and capsid amino acid sequences of prototypic
mon-99CMCML1 accession No. AY340701 isolated from mona monkey
r spot-nosed monkey (Cercopithecus nictitans); SIVmus-01CM1085
IVmnd1, accession No. M27470, from mandrill (Mandrillus sphynx) and
za). Dots represent fully conserved residues and deletions are indicated
the chimeric GagPol constructs (MACA and CA). The beginning of CA








































































































Figure 2 Chimeric constructs that express lentiviral capsids and stable expression of primate TRIM5 in CHO cells reproduce TRIM5α
restriction specificity. (A) Wild-type SIVmac GagPol expression vector and chimeric GagPol constructions were used to obtain single-round
infectious virions, containing an SIVmac vector with eGFP and the vesicular stomatitis virus G fusion protein. Supernatants were harvested 48 h
later and pelleted by ultracentrifugation through a 20% sucrose cushion. Viral preparations that gave 20% GFP positive cells on CHO cells were
immunoblotted. Gag proteins were detected using sera from HIV-2 infected patients. (B) Stable expression of TRIM5α proteins in CHO cells. Cell
extracts were obtained from CHO cells and CHO cells transduced with vectors encoding HA-tagged TRIM5α from human (hu-TRIM5α),
chimpanzee (cpz-TRIM5α), African green monkey (agm-TRIM5α), or rhesus monkey (rh-TRIM5α). Immunoblotting was performed with an anti-HA
monoclonal antibody. Actin was probed as loading control. (C) Cell extracts were obtained from CHO cells transduced with vectors encoding
HA-tagged TRIM5CypA proteins from owl monkey (owl-TRIMCypA), Macaca mulatta (mamu-TRIMCypA) or Macaca fascicularis (mamu-TRIMCypA).
TRIM-RanBP2Cyp corresponds to a synthetic protein constructed after fusing TRIM5 Linker 2 region of owl-TRIMcypA with the human RanBP2-Cyp
sequence. (D) Infection efficiency of serial dilutions for each chimera in CHO hamster cells. (E) Restriction specificity in TRIM5α-expressing CHO cell
lines. CHO cells stably expressing hu-TRIM5α (solid bars) or agm-TRIM5α (open bars) were challenged with virions harboring wild-type SIVmac or HIV-1
CA, or chimeric SIVmac-HIV-1 (MACA or CA) Gag proteins. GFP-positive cells were enumerated by flow cytometry. Ratios of percentage of infected
cells in TRIM5α-expressing CHO cells over CHO control cells were determined. Results are expressed as means from at least three independent
experiments. Error bars represent the standard error of the mean. Unpaired two-tailed Student’s t-test was used to assess significance and
P-values < 0.001) are indicated with asterisks.
Mamede et al. Retrovirology 2013, 10:77 Page 4 of 15
http://www.retrovirology.com/content/10/1/77inhibition pattern of human or simian TRIM5α proteins
with circulating SIV isolates. We carried out single-
round VSV-G pseudotyped eGFP virus infections of
CHO cells stably expressing various TRIM5α alleles. In-
fectivity of a control N-tropic MLV, which is restricted
by hu or cpz-TRIM5α, was significantly reduced (ratio
0.3, p < 0.001) while the B-tropic MLV negative control
remained unaffected, thus confirming the restriction
specificity of our model (Figure 3A and B). As shown in
Figure 3A and B, the overall restriction profiles of hu
and cpz-TRIM5α were very similar. With the excep-
tion of a partial restriction activity against HIV-G89V
(ratio dropped to 0.6, p < 0.001), which has alreadybeen observed by others [32,64] none of the other pri-
mate lentiviruses tested were significantly restricted.
We next assessed the restriction patterns of the rh and
agm-TRIM5α (Figure 3C and D). While SIVmac remained
unrestricted, as expected, both rh and agm-TRIM5α sig-
nificantly restricted all of the HIV-1 CA recombinants,
with infectivity ratio dropping from 0.1 to 0.4 as compared
to SIVmac (p < 0.01 and 0.001). Although the two primate
TRIM5α alleles strongly restricted HIV-1 and HIV-G89V,
restriction of the SIV isolates varied considerably. Thus,
SIVmon and SIVmnd1 were significantly but only partially
restricted (ratio of 0.6 or higher, p < 0.001) and SIVgsn,
SIVmus-1 and SIVcol were not detectably restricted by
Figure 3 Distinctive patterns of restriction are due to the types of primate TRIM5α isoform and the type of circulating SIV capsid that
is targeted. (A) Restriction profiles of different primate TRIM5α isoforms against circulating SIV CA are determined in control CHO cells or CHO
cells stably expressing (A) the human, (B) the chimpanzee, (C) the rhesus, or (D) the African green monkey TRIM5α proteins. Virion preparation
and infection efficiency were as described in the legend of Figure 2. Additional control virions were used, including those with the CA of
TRIM5α-susceptible N-tropic MLV (MLV-N) and TRIM5α-resistant MLV-B. Results were obtained from at least three independent experiments for each
combination. Unpaired two-tailed Student’s t-test was used to assess significance. SEM and P-values are indicated (** P < 0.01; *** P < 0.001).
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the pattern of susceptibility to TRIM5α of the different
SIV did not parallel the virus phylogeny, as illustrated, for
instance, by SIVmon that is closely related to SIVgsn and
SIVmus-1.
SIV CA-CypA interaction is a widespread but not a
universal phenotype
We next tested whether susceptibility of circulating SIV
isolates to certain simian TRIM5α proteins correlated
with CypA-CA interactions. CypA is a host cellular
factor that is essential for efficient HIV-1 replication
in human cells through its interaction with CA [30].
Several lentiviruses bind CypA with high affinity but
others, such as SIVmac, do not [65,66]. We therefore
investigated the ability of CA from circulating SIV iso-
lates to interact with CypA by taking advantage of a
TRIMCyp fusion protein naturally present in owl mon-
keys [35,36]. Owl-TRIMCyp harbors a CypA domain that
shares 97% identity with human CypA (Figure 4A). Our
model was further validated with the CHO cells that
stably express owl-TRIMCyp as these cells reproduced
the expected restriction of HIV-1 with no restrictionagainst the HIV-1 G89V mutant, which does not bind
CypA (Figure 4B). With regard to other circulating SIV,
we found that infectivity of SIVmnd1 was consider-
ably reduced (drop of infectivity ratio to less than 0.4,
p < 0.001) and confirmed that SIVgsn was susceptible
to owl-TRIMCyp restriction [67] (Figure 4B).
We further verified that the TRIMCyp-mediated re-
striction in hamster cells was indeed due to binding to
the CypA domain by using cyclosporine A (CsA), a com-
petitive inhibitor which binds to CypA (Figure 4C). How-
ever, we found that the ability of SIVmnd1 and SIVgsn
to infect human cells does not seem to involve a CypA
dependence, since, in contrast to HIV-1, CsA treatment
did not inhibit, but rather enhanced, infectivity (data not
shown), in agreement with results obtained by others with
SIVmac [68]. Amongst the SIV that we observed to be
resistant to TRIMCyp restriction, were SIVcol and,
interestingly, SIVmon and SIVmus-1 which are closely
related to SIVgsn (Figure 4B). The CypA binding loop
of lentiviral CA is the proline-rich sequence comprised
between helices 4 and 5 on HIV-1 CA [69]. By using
the CA crystal structure of HIV-1 bound to human CypA




















































Figure 4 Natural primate TRIMCypA fusion proteins show heterogeneous patterns of restriction against circulating SIV CA. (A) Highly
conserved sequences between human CypA and the carboxy terminal CypA domains of primate TRIM5CypA fusion proteins; also shown is the
related, but more divergent, carboxy terminal Cyp-like domain of the Nup158/RanBP2 nucleoporin (see text); (−) identical residues. (B) Restriction
pattern of a CHO cell line stably expressing owl-TRIMCypA fusion protein against different lentiviral capsids as compared to infection of control
CHO cells. (C) assessment of CypA dependence of the owl-TRIMCypA restriction against prototypic wt and mutant HIV-1 capsid constructs and
against two circulating SIV capsids, assayed in the absence (−) or the presence (+) of cyclosporine A (CsA), a CypA inhibitor. (D) Infection titers
of chimeric CA viruses on CHO cells stably expressing either TRIMCypA from Maccaca fascicularis (mafa-TRIMCypA) or (E) TRIMCypA from
Maccaca mulatta (mamu-TRIMCypA) were compared to titers on control CHO cells as described above in (B) with the additional use of a
chimeric SIVmac GagPol construct containing MACA of HIV2ROD as control. Infectivity was calculated as indicated in Figure 2. All results were
compiled from at least three independent experiments for each combination. Unpaired two-tailed Student’s t-test was used to assess
significance. SEM and P-values < 0.001 (asterisks) are indicated.












Figure 5 Structure of lentiviral capsids bound to human CypA reveals distinctive groups of interactions amongst the different circulating
SIV capsids. (A) HIV-1 CA crystal structure (gold ribbon) bound to human CypA (grey ribbon) as compiled in the databanks (PDB: 1M9C; http://
www.resbiorg/pdb/explore.do?structureId=1m9c). The Glycine and proline residues at position 89 and 90, respectively, are indicated in red and with
an arrow on HIV-1 CA and at the equivalent positions on the different circulating SIV. HIV-1 CA-CypA crystal structure is used as template to
predict the CA structure of different circulating SIV (see Figure 1 legend). (B) CA of SIVmnd-1, shown as a blue ribbon, is superimposed on HIV
CA. (C) Superimposition of the three CA that belong to the SIVgsn lineage, SIVgsn, in blue; SIVmon, in pink; and SIVmus-1, in green. (D) CA of
SIVcol, in pink, superimposed with HIV-1 CA.
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SIVmnd1 (Figure 5B), those of the three SIV of the
SIVgsn lineage (Figure 5C) and that of SIVcol (Figure 5D).
We found that the CypA-binding loop of SIVmnd1
superimposed closely with that of HIV-1 while the SIVcol
loop, which is shorter, does not (Figure 5B and D). Inter-
estingly, as shown in Figure 5C, within the SIVgsn lineage,
the change of A (CA SIVgsn) to Q (CA SIVmon and
SIVmus-1) introduced a subtle conformational change,
that significantly altered the direct contact with the
hydrophobic pocket of CypA, even if the target proline ′90′
remained present in the middle of the loop. Therefore,
structural predictions of CA-CypA interactions as shownin Figure 5 are in accordance with the TRIM-CypA re-
striction phenotype.
Curiously, while TRIMCyp has been first described
in owl monkeys, a New-World primate, fusion of
the CypA coding sequence with TRIM5 has since
been described in at least two Old-World macaques
species (mafa-TRIMCypA in Macaca fascicularis and
mamu-TRIMCypA in Macaca mulatta,), illustrating
the strong recurrent selection pressure of this event
during primate evolution [37]. As these different
CypA sequences show some amino acid divergence
(Figure 4A), we tested whether SIVgsn and SIVmnd1
were susceptible to mafa-TRIMCyp, like HIV-1, or
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both SIVmnd1 and SIVgsn displayed an HIV-1-like
phenotype, with a strong restriction measured with
mafa-TRIMCyp (infectivity ratio below 0.4, p < 0.001),
while neither was susceptible to mamu-TRIMCyp
(Figure 4D and E). The specific restriction pattern of
mamu-TRIMCyp was fully reproduced in our model since
a very strong restrictive effect was observed, as expected,
on the HIV-2 construct (infectivity ratio below 0.2,
p < 0.001) (Figure 4E).
Nup358/RanBP2 depletion decreases SIVmac, SIVgsn and
SIVmnd1 infectivity
In a global siRNA screening study, Nup153 and Nup358/
RanBP2, two nucleoporins of the nuclear pore complex
(NPC) were identified as essential for nuclear import of
HIV-1 DNA [42]. Interestingly, Nup358/RanBP2, which
localizes at the cytoplasmic side of the NPC, possesses a
CypA-like domain that has been suggested to play an
important role in viral infectivity through direct binding





























Figure 6 HIV and circulating SIV capsids vary in their dependence
(A) Specific down modulation of Nup358/RanBP2 in HEK-293T cells by target
directed against either the luciferase gene (siLuc) or Nup153 (siNup153) or Nu
polyclonal antibody directed against Nup358/RanBP2 (upper panel) or a m
(lower panel). (B) Infection of Nup358/RanBP2-depleted HEK-293T cells as
of eGFP-positive cells as described in Figure 2 and Figure 3 legends using
circulating SIV capsid constructs. (C) Restriction activity in CHO cells stably
to CHO cells. Cells were infected as described above with virions harborin
and circulating SIV. All results were obtained from at least three independ
was used to assess significance. SEM and P-values < 0.001 (asterisks) are inIn the context of our study, we examined whether
human Nup358/RanBP2 interacted with the CA of the
circulating SIV and investigated the impact of Nup358/
RanBP2 depletion on infection with our chimeric CA
viruses. Nup358/RanBP2 siRNA were transfected into
HEK-293T cells and the knockdown of the protein was
verified by immunoblotting using a Nup358/RanBP2 spe-
cific antibody (Figure 6A). Consistent with previous re-
ports, HIV-1 was affected by Nup358/RanBP2 depletion
while, on the contrary, infectivity of HIV-1 G89V slightly
increased (Figure 6B). Furthermore, we observed that
infectivity of SIVgsn and SIVmnd1 were also significantly
reduced (p < 0.001) after Nup358/RanBP2 depletion. In
contrast, SIVmus-1, SIVmon and SIVcol infections remained
unaffected. Nevertheless, despite this pattern, there was
no strict relationship between dependence on Nup358/
RanBP2 for optimal infection and CypA-CA interaction.
Indeed, in contrast with previous findings that used an
shRNA approach [63], we found that owl-TRIMCyp in-
sensitive SIVmac251 was also significantly susceptible to













on Nup358/RanBP2 for the optimal infection of human cells.
ed siRNA. Whole-cell extracts of HEK-293T cells transfected with siRNA
p358/RanBP2 (siNup358/RanBP2), were immunoblotted with a rabbit
onoclonal antibody directed against lamin B, used as loading control
compared to infection of siLuc-treated cells were determined as ratio
MLV-B, wt and chimeric HIV-1 constructs, HIV-2ROD, SIVmac, and
expressing a synthetic TRIM-RanBP2Cyp fusion protein as compared
g CA from wt SIVmac and HIV-1, chimeric HIV-1 constructs, HIV-2ROD,
ent experiments with each CA. Unpaired two-tailed Student’s t-test
dicated.
BA
Figure 7 Optimal infection of human cells mediated by both
HIV-1 and HIV-2 capsids is dependent on Nup153 while capsids
of SIVmac and circulating SIV capsids are mildly or not
dependent on Nup153. (A) Specific down modulation of Nup153
in HEK-293T cells (siRNANup153) as compared to control siLuc-treated
cells. Cells were analyzed as described in the Figure 6 legend.
(B) Infection of Nup153-depleted HEK-293T cells as compared to
infection of control siLuc-treated cells were determined as described
above using MLV-B, wt and chimeric HIV-1 constructs, HIV-2ROD,
SIVmac, and circulating SIV CA constructs. Results were obtained
from at least three independent experiments with each CA.
Unpaired two-tailed Student’s t-test was used to assess significance.
SEM and P-values (* P < 0.05, *** P < 0.001) are indicated.
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Nup358/RanBP2 depletion.
We further assessed whether susceptibility to Nup358/
RanBP2 depletion in HEK-293T cells was related to binding
to the CypA-like domain of the protein. For this purpose,
we generated a synthetic TRIM-RanBP2Cyp protein that
comprised the RBCC domain of owl-TRIMCypA in which
we replaced the original owl CypA domain by that of
Nup358/RanBP2 (Figure 4A). Stable expression of this
TRIM-Nup358/RanBP2 CypA fusion protein in CHO cells
was confirmed by western blot using an anti-HA antibody
(Figure 2C). In agreement with a previous report, we
observed that HIV-1 was tightly restricted by TRIM-
RanBP2Cyp [63]. However, we found that, with the excep-
tion of HIV-2ROD, none of HIV-1 G89V, SIVmac or the
circulating SIV isolates were restricted by TRIM-RanBP2Cyp
(Figure 6C). These results indicate that the direct interaction
of Nup358/RanBP2 by circulating SIV does not appear to
be mediated via its Cyp-like domain. Whether the Cyp-like
domain of Nup358/RanBP2 is actually required for HIV-1
infectivity in vivo is still subject to debate [62,71].
Circulating SIV do not necessarily use Nup153 or Nup358/
RanBP2, in contrast to both HIV types
Nup358/RanBP2 and Nup153 are on opposing sides of
the NPC, respectively cytoplasmic or nuclear side [72,73].
Depletion of Nup153 inhibits HIV-1 infection and CA is
involved in this dependence [54]. CypA appears to also
play a role in directing HIV-1 into a nuclear entry path-
way that involves Nup358/RanBP2 and in which recruit-
ment of Nup153 plays a role [52,63]. Since our results
on Nup358/RanBP2 dependence of viruses harboring
Gag domains derived from different SIV isolates do not fol-
low this observation, we further tested the infectivity of
the Nup358/RanBP2-susceptible SIVmac, SIVgsn, SIVmnd1
on Nup153-depleted cells. In parallel, we monitored the
infectivity of the Nup358/RanBP2-insensitive SIVmon,
SIVmus-1, and SIVcol. Protein expression level was
checked by immunoblotting using a Nup153 specific
antibody (Figure 7A). In addition, we verified that Nup153
depletion did not impact on the expression level of
Nup358/RanBP2 by immunoblotting using a Nup358/
RanBP2 specific antibody (Figure 6A). In agreement
with others’ results, we found that both HIV-1 and
HIV-2ROD infection of Nup153 knockdown HEK-293T
cells was significantly inhibited while HIV-1 G89V in-
fection remained unaffected as compared to the infection
of control cells (Figure 7B). Moreover, Nup153 depletion
slightly inhibited infection by SIVmac (ratio 0.5; p < 0.05)
and SIVmon (ratio 0.7; p < 0.05), with either no significant
inhibitory effect on the other circulating SIV or even a sig-
nificantly increased infection as observed for SIVmnd1
(ratio 1.5; p < 0.05) (Figure 7B). This opposite effect on
SIVmnd1 infection as compared to the Nup358/RanBP2knockdown suggested that Nup153 may interfere with the
engagement of another nucleoporin preferentially recruited
by some of the circulating SIV.
Overall, CA appear to dictate the use of alternative path-
ways that can substitute for the CypA, Nup358/RanBP2
and Nup153 chain of engagement in the nuclear import
of lentiviruses in human cells. However, dependence on
the CypA, Nup358/RanBP2 and Nup153 CypA pathway
seems to be conserved in both HIV-1 and HIV-2 al-
though they are of different zoonotic origins. Taken
ltogether, our results question whether this pathway re-
flects a required adaptation to human cells for efficient
lentiviral infection.
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Despite high exposure to lentiviruses of human popula-
tions in Sub-Saharan Africa, zoonotic transmissions of
SIV do not appear to be so common [74]. Here, we eval-
uated the likelihood of new cross-species transmissions
by investigating the interactions of CA from naturally
circulating SIV isolates to cellular host factors that
block or enhance HIV-1 replication at the early stages
of the viral life-cycle. We found that TRIM5α, one of
the species-specific barriers to HIV-1 in monkeys, is
unlikely to provide a protection from the crossing of
circulating primate lentiviruses to humans. So far, no
SIV is known to be restricted by hu-TRIM5α and none
of the CA from circulating SIV isolates tested here, in-
cluding SIVcol, the most divergent SIV, were suscep-
tible to either human or chimpanzee TRIM5α. This was
not surprising given that the PRYSPRY domain of cpz-
TRIM5α is closely related to that of hu-TRIM5α. SIVcpz,
the ancestor of the HIV-1 groups M and N, emerged from
the recombination of two lineages of SIV that infect
monkeys [5,75]. The CA-containing 5′ part of the SIVcpz
genome is related to SIV found in red-capped mangabey
[76] whereas the env gene-containing 3′ part is related
to the SIVgsn lineage, a lineage that comprises SIV that
infect three Cercopithecus species [5,77]. Therefore, since
the CA of the phylogenetically closely related SIVmon,
SIVmus-1 and SIVgsn are not sensitive to cpz-TRIM5α,
any of the three might have been involved in the re-
combination that gave rise to SIVcpz. Moreover, since
chimpanzees are known to predate on a variety of lower
primate species, the fact that cpz-TRIM5α does not
seem capable of inhibiting SIV infection suggests that
chimpanzees might acquire other SIV in the context of
predation, which in turn may generate SIV with new
abilities to adapt and spread into humans.
Hu-TRIM5α can block gammaretroviruses such as
N-tropic murine leukemia virus (N-MLV), as well as
lentiviruses such as feline immunodeficiency virus (FIV)
and equine infectious anemia virus (EIAV) [24,78,79],
but the sole known example of a primate retrovirus that
is susceptible to hu-TRIM5α is ptERV1, an endogenous
gammaretrovirus identified in the chimpanzee genome
and absent in humans [80]. On the other hand, rh and
agm-TRIM5α display a broad antiretroviral activity to-
wards gammaretroviruses as well as lentiviruses, including
primate lentiviruses [17,81]. Thus, the positive selective
pressure on hu-TRIM5α is likely to be a retrovirus with a
capsid conformation that is incompatible with primate
lentivirus restriction. However, the ability of rh and agm-
TRIM5α to restrict a wide range of lentiviruses reinforces
the fact that these primate species have most likely been
challenged by lentiviral infections.
The interaction of retroviral CA with CypA is a char-
acteristic that was present in ancient retroviruses andthat has been preserved throughout lentiviral evolution
[82]. However, among “modern“ lentiviruses, the CypA-
CA interaction is a widespread yet not universal feature
[65,67]. While host CypA is essential for efficient HIV-1
replication in human cells, its role in controlling the in-
fectivity of other lentiviruses remains unestablished [65].
The most critical target amino acids in CA for CypA
binding are the glycine residue at position 89 (G89) and
the proline residue at position 90 (P90) [83] although
sequences flanking these two residues can also contrib-
ute significantly to CypA recognition [84]. Furthermore,
Lin and Emerman have shown that the length of the
loop that harbors G89 can also influence CypA inter-
action [65]. Our results with SIVgsn CA, which bound
CypA domain of owl and mafa-TrimCyp, and CA of the
related SIVmon and SIVmus-1, which did not, are con-
sistent with the observations by others [85] that an A at
position G89 maintains CypA binding while a Q does
not. Interestingly, all SIVmon and SIVmus circulating
isolates identified so far harbor a Q, while the SIVgsn
isolates have an A89 [2,5]. The phylogenetic relationship
between SIVmon, SIVmus-1, SIVmus-2 and SIVgsn could
reflect ancient transmissions of an ancestor SIV to differ-
ent primate species that shared the same habitats [2,77].
However, within this SIV lineage, only SIVgsn appears
to bind owl-CypA, suggesting that SIVgsn CA may require
the CypA interaction in its host species, while CA of
SIVmon and SIVmus would have evolved without this
requirement upon adaptation to their new hosts. Whether
the CypA-CA interaction might be detrimental for the
spreading of SIV into certain hosts will be more easily
assessed after evaluating the interaction of the CA with
the CypA of the natural host. As recently suggested,
cyclophilins may have thus played a major role in the
determination of SIVmac tropism [68].
CypA as well as Nup153 and Nup358/RanBP2 have
recently been described to be a part of a pathway that
mediates HIV-1 nuclear import [53-55,57] and CA which
plays a major role in this property, determines the require-
ments for these proteins [45,52,54,59,63]. Since, we found
that HIV-2Rod CA exploits the same pathway, it would be
of importance to test whether this dependence is shared
by primary isolates of HIV in their natural host cells.
Nonetheless, we observed that Nup358/RanBP2 and
Nup153 are not required for efficient infection by circulat-
ing SIV isolates and that the direct binding of Nup358/
RanBP2 via its Cyp-like domain does not seem neces-
sary. Interestingly, in HEK-293T cells, the knockdown of
Nup358/RanBP2 or Nup153 has opposite effects on in-
fectivity driven by some circulating SIV: we found that
infectivity of viruses encoding CA derived from SIVmnd1
decreases with the former and increases with the latter.
However, we demonstrated that the susceptibility to
Nup358/RanBP2 depletion is not completely correlated
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and HIV-2 were restricted upon infection of CHO cells
stably expressing TRIM-RanBP2Cyp whereas SIVgsn and
SIVmnd-1 were not (Figure 6C). As previously described
we found that SIVmac was susceptible to Nup153 deple-
tion [45,54] and in contrast to previous findings, was
also susceptible to Nup358/RanBP2 depletion [63]. These
results may be explained by a different protein knockdown
approach (siRNA versus shRNA) and/or the different
human cell lines used in the two studies (HEK-293T ver-
sus HeLa). Nevertheless, the proposed role of CypA in
directing the virus towards the use of a nuclear entry
pathway involving Nup358/RanBP2 and Nup153, as it
has been suggested for HIV-1, does not seem to hold
true with SIVmac, given its inability to bind CypA.
It will be interesting to test whether these circulating
SIV isolates are susceptible to depletion of TNPO3, a
karyopherin known to transport SR family proteins, which
has been also implicated in the Nup358/RanBP2-Nup153
pathway [63]. Collectively, these results suggest that a
pathway including at least Nup153, Nup358/RanBP2
and CypA for nuclear entry, is not conserved between
primate lentiviral lineages. Therefore, it could also be
interesting to study the relationship between Nup358/
RanBP2-Nup153 in their respective host species during
SIV infections.
Conclusions
Productive infection of SIV in a new species involves
necessary interactions with multiple cellular proteins
within the infected host cell. Overall, we found that cir-
culating SIV CA present a variety of phenotypes with
regard to CA-interacting restricting or facilitating fac-
tors that do not appear to restrict these circulating SIV.
Thereby, our observations highlight the use of distinct
strategies to enter the nucleus, which may reflect species–
specific requirements of co-factors by viruses. Under-
standing the lentiviral capsid/host protein interactions
during the early steps of infection will be useful to de-
termine the factors that contribute to a successful or
dead-end simian-to-human transmission and also to fur-
ther develop novel targets to hinder HIV replication.
Methods
Chimeric gag-pol SIVmac expression plasmids
The HIV-1 and HIV-1G89V gag fragments (matrix-capsid
(MACA) or capsid (CA) were PCR amplified from the
p8.91 and p8.91G89V gag-pol expression plasmids, re-
spectively [25,86]. The HIV-2 MACA fragment was amp-
lified from a HIV-2ROD plasmid. MACA and CA SIV from
the SIVgsn lineage were PCR amplified directly from
uncultured lymphocyte DNA of Cercopithecus monkeys
(C. mona, C. cephus, and C. nictitans) [5,77] and from
the SIVcolCGU1 from mantled guereza (Colobus guereza)[87]. MACA and CA from SIVmnd1 were derived from
PBMC DNA (a kind gift of Dr Roques, CEA, Fontenay-
aux-Roses, France) obtained from an infected mandrill
(Mandrillus sphinx) with SIVmnd1 GB1 strain [88]). PCR
products were sub-cloned into the BssHII-ApaI (MACA)
or the DraIII-AflII (CA) sites of a pUC19 plasmid containing
an NdeI-SbfI fragment of a gag-pol SIVmac251 expres-
sion plasmid (pAd-SIV4) [89]. The pUC19/NdeI-SbfI
vector was first subjected to in vitro mutagenesis with
the QuikChange mutagenesis kit (Stratagene) to create
BssHII and ApaI restriction sites by synonymous muta-
tions. The chimeric NdeI-SbfI fragments were then cloned
into an NdeI-SbfI digested pAd-SIV4 vector to obtain the
chimeric gag-pol SIVmac expression plasmids.
Generation of cells stably expressing TRIM5 variants
The full-length cDNA from different TRIM5α proteins (hu-
TRIM5α, cpz-TRIM5α and agm-TRIM5α) were obtained
from RT-PCR amplification of RNA from HeLa cells, from
a chimpanzee (Pan troglodytes verus) PBMC (kindly pro-
vided by Dr. Heinz Ellerbrok, Robert Koch Institute, Berlin,
Germany) and from Vero cells, respectively. The full-length
cDNA from rh-TRIM5α and owl-TRIMcypA were PCR
amplified from plasmids pLPCX-TRIM5αrh and pMIG-
TRIMCyp, respectively, both were obtained from the NIH
AIDS reagent program. Mafa-TRIMcypA and mamu-
TRIMcypA were kindly provided by Dr. Greg Towers
(University College London, UK) [90,91]. To construct
TRIM-RanBP2CypA fusion protein, the RanBP2-Cyp
like sequence was PCR-amplified from Jurkat cell cDNA
and cloned in place of the CypA motif of owl-TRIMcypA.
After purification, all amplified PCR products were
subcloned into a pCR4-TOPO vector according to the
manufacturer's instructions (Invitrogen), followed by se-
quencing of three independent clones. These inserts
were then cloned into the NotI and BglII sites of a retro-
viral vector containing a C-terminal hemagglutinin (HA)
derived from pLXSN [92]. To produce MLV particles,
HEK-293T cells were then co-transfected with the pLXSN-
based retroviral vectors encoding the various HA-tagged
TRIM5 variants along with plasmids expressing MLV
Gag-Pol (pC57GP) [93] and the vesicular stomatitis virus
(VSV) G envelope glycoprotein (pCSIG) [94]. After 48 h,
retroviral virions were harvested in supernatants and used
to transduce CHO cells followed by selection in 200 μg/ml
G418 (Invivogen).
Infection with lentiviral virions harboring wt and
chimeric capsids
HEK-293T and CHO cells were cultivated in Dulbecco
modified Eagle medium (DMEM) supplemented with
10% fetal bovine serum, non-essential amino acids and
100 U penicillin/ml and 0.1 mg streptomycin/ml at 37°C
and 5% CO2-air atmosphere.
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green fluorescent protein (GFP)-reporter gene were gen-
erated by co-transfecting HEK-293T cells with three ex-
pression vectors: (i) a gag-pol expression vector (p8.91
for HIV and pAd-SIV4 for SIVmac and chimeric SIV)
(ii) VSV-G envelope glycoprotein expression vector (pCSI-G)
allowing an efficient entry into the mammalian cell lines
and (iii) GFP lentiviral viral vectors derived either from
HIV (pSIN-CSGW) [95] or SIV (GAE-SFFV-GFP-WPRE)
[89]. Virion-containing culture supernatant was har-
vested 48h after transfection and filtered through a
0.45 μm-pore-size filter. When necessary, retroviral super-
natants were concentrated 100 fold by ultra-centrifugation
through a 20% sucrose cushion in a SW28 rotor at
25000 rpm at 4°C for 2 hours. All viruses were stored
at −80°C until use.
Viral stocks were titrated on non-restricting CHO cells
by counting the number of GFP positive cells, by flow
cytometry, two days after transduction. All infections
were performed on 2×104 cells in 96-well plates, with
challenging viruses at M.O.I. that yielded 5 to 30% GFP-
positive infected cells, in the presence of polybrene at a
concentration of 4 μg/ml. When required, cyclosporin-A
(CsA) (Sigma-Aldrich) was added during infection at a
concentration of 5 μg/ml. Cells were then incubated at
37°C/5%CO2. GFP-positive cells were enumerated 48h
later by flow cytometry on a FACSCalibur instrument
(Becton Dickinson) and 10,000 events were collected.
Data analyses were performed using FlowJo 7.6.1 soft-
ware (Tree Star).
siRNA transfection
Sequences of siRNA were as follows: 5′ - GGCAGCUCUA
CCAAAUGUtt - 3′ for the Nup153 (position 2593–2615)
(NM_005124) [96]; 5′- GGCUCCAAAGAGCGGAUUUtt-3′
from Saitoh et al. [97], 5′-GCGCGAAAUUGUUUCGU-
Utt-3′ (position 3719 to 3738) and 5′-GCA-AAC-CAC-
GUU-AUU-ACU-Att-3′ (position 8704 to 9723) for
Nup358/RanBP2 (accession number NM_006267.4).
HEK-293T cells were transfected with 300 pmoles of each
specific RNA duplex using Oligofectamine (Invitrogen)
according to the manufacturer’s instructions. A siRNA
directed against firefly luciferase was used as control.
Forty-eight hours after transfection, cells were trypsinized,
plated in 96-well plates, infected with GFP reporter vi-
ruses and analyzed by flow cytometry 2 days later. In
some experiments, a combination of multiple siRNAs
was used (total of 300 pmol).
Immunoblotting
CHO cells stably expressing HA-tagged TRIM5 variants
were lysed in 100 mM NaCl, 50 mM Tris (pH 7.5) and
1% Triton X-100 containing protease inhibitors (Sigma-
Aldrich). Proteins were separated on a 10% acrylamidegel, transferred onto PVDF membrane and probed with
a rat anti-HA antibody (3F10, Roche Applied Science).
A peroxidase-conjugated goat anti-rat (SouthernBiotech)
was used as secondary antibody. Loading was controlled
by probing with a β-actin antibody. For CA detection,
conditioned cell-free supernatants of transfected HEK-
293T cells were pelleted through a 20% sucrose layer in
TEN Buffer (10 mM Tris.HCL pH7,5; 100 mM NaCL;
1 mM EDTA) at 25000 rpm for 2h30 at 4°C in a SW
40 Ti rotor. CA of pelleted viruses were monitored using
sera from HIV-2 infected patients and anti-human-IgG-
HRP IgG (Sigma-Aldrich) as primary and secondary anti-
bodies, respectively.
Protein depletion by siRNA in HEK-293T cells was
monitored by immunoblotting using a rabbit polyclonal
antibody against Nup358/RanBP2 (ab64276, Abcam) and
mouse Nup153 antibodies (ab24700 (Abcam) with a
peroxidase-conjugated goat anti-rabbit and anti-mouse
as secondary antibodies, respectively (Sigma-Aldrich).
Lamin-B was used as a loading control.
Computational structure predictions
The computer modeling of N-terminal CA structure from
the SIVgsn lineage, SIVmnd1 and SIVcol was performed
with the raptorX server http://raptorx.uchicago.edu) [70],
using the experimental CA crystal structure of HIV-1
bound to human CypA (PDB: 1M9C; http://www.rcsb.
org/pdb/explore.do?structureId=1m9c) as a structural
template. The multiple sequence alignments of the target
and template sequences were performed using ClustalX
[98]. The predicted CA structures were visualized using
the PyMOL 1.4.1 Linux version (http://pymol.org/citing).
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